CHARACTERIZATION OF DOPAMINE AND SEROTONIN UPTAKE INHIBITORY EFFECTS OF TETRAHYDROAMINOACRIDINE IN RAT-BRAIN

被引:16
作者
JOSSAN, SS [1 ]
ADEM, A [1 ]
WINBLAD, B [1 ]
ORELAND, L [1 ]
机构
[1] KAROLINSKA INST, HUDDINGE HOSP, DEPT GERIATR MED, HUDDINGE, SWEDEN
来源
PHARMACOLOGY & TOXICOLOGY | 1992年 / 71卷 / 03期
关键词
D O I
10.1111/j.1600-0773.1992.tb00548.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The effects of 1,2,3.4-tetrahydro-9-aminoacridine (THA) on uptake rates of radioactive 5-hydroxytryptamine (5-HT) and dopamine were investigated in rat diencephalon and striatal homogenates. respectively. Six and eight muM of THA were needed to inhibit 50% of dopamine and 5-HT uptake rates. Kinetic parameters, K(m) and V(max), using six different concentrations of dopamine and 5-HT were estimated in the presence or absence of THA. A significant decrease in V(max) without any change in K(m) values was observed for both dopamine and 5-HT in the presence of THA. The results show that THA is a non-competitive uptake inhibitor of dopamine and 5-HT in the nerve terminals. The re-uptake blocking effect of THA on dopaminergic and serotonergic neurones. following THA treatment, might lead to increased levels of these monoamines in brains of Alzheimer patients and contribute in the therapeutic effects of the drug.
引用
收藏
页码:213 / 215
页数:3
相关论文
共 19 条
  • [1] TETRAHYDROAMINOACRIDINE INHIBITS HUMAN AND RAT-BRAIN MONOAMINE-OXIDASE
    ADEM, A
    JOSSAN, SS
    ORELAND, L
    [J]. NEUROSCIENCE LETTERS, 1989, 107 (1-3) : 313 - 317
  • [2] BRADFORD HF, 1985, CHEM NEUROBIOLOGY IN
  • [3] CARLSSON A, 1959, PHARMACOL REV, V11, P490
  • [4] DEMAREST KT, 1980, J PHARMACOL EXP THER, V215, P461
  • [5] FURTHER ANALYSIS OF THE NEURO-PHARMACOLOGICAL PROFILE OF 9-AMINO-1,2,3,4-TETRAHYDROACRIDINE (THA), AN ALLEGED DRUG FOR THE TREATMENT OF ALZHEIMERS-DISEASE
    DRUKARCH, B
    LEYSEN, JE
    STOOF, JC
    [J]. LIFE SCIENCES, 1988, 42 (09) : 1011 - 1017
  • [6] TACRINE IN ALZHEIMERS-DISEASE
    EAGGER, SA
    LEVY, R
    SAHAKIAN, BJ
    [J]. LANCET, 1991, 337 (8748) : 989 - 992
  • [7] TETRAHYDROAMINOACRIDINE LECITHIN COMBINATION TREATMENT IN PATIENTS WITH INTERMEDIATE-STAGE ALZHEIMERS-DISEASE - RESULTS OF A CANADIAN DOUBLE-BLIND, CROSSOVER, MULTICENTER STUDY
    GAUTHIER, S
    BOUCHARD, R
    LAMONTAGNE, A
    BAILEY, P
    BERGMAN, H
    RATNER, J
    TESFAYE, Y
    SAINTMARTIN, M
    BACHER, Y
    CARRIER, L
    CHARBONNEAU, R
    CLARFIELD, AM
    COLLIER, B
    DASTOOR, D
    GAUTHIER, L
    GERMAIN, M
    KISSEL, C
    KRIEGER, M
    KUSHNIR, S
    MASSON, H
    MORIN, J
    NAIR, V
    NEIRINCK, L
    SUISSA, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (18) : 1272 - 1276
  • [8] Gottfries C G, 1988, Compr Gerontol C, V2, P47
  • [9] ALZHEIMERS-DISEASE AND SENILE DEMENTIA - BIOCHEMICAL CHARACTERISTICS AND ASPECTS OF TREATMENT
    GOTTFRIES, CG
    [J]. PSYCHOPHARMACOLOGY, 1985, 86 (03) : 245 - 252
  • [10] INHIBITION OF CHOLINESTERASES BY TETRAHYDROAMINACRIN
    HEILBRONN, E
    [J]. ACTA CHEMICA SCANDINAVICA, 1961, 15 (06): : 1386 - &